| Description | The anti- antibody has been developed to specifically target human BDNF and inhibit its interaction with the TrkB receptor, demonstrating an IC₅₀ range of 0.1-0.5 nM. The immunogen utilized for the development of this molecule involved the immunization of chickens with a mixture of human BDNF. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | A mixture of human BDNF. |
| Epitope | C-terminus |
| IC50 | 0.1-0.5 nM |
| Affinity | KD = 34 ± 5 nM |
| Isotype | Human IgG1, lambda |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | Inhib; ELISA; Neut; FC |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | BDNF |
| Alternative Name | Brain Derived Neurotrophic Factor; Neurotrophin; Abrineurin; Brain-Derived Neurotrophic Factor; ANON2; BULN2 |
| Gene ID | 627 |
| UniProt | P23560 |
| Related pathway | Apoptotic Pathways in Synovial Fibroblasts and Downstream signaling of activated FGFR2 |
| Research Area | Signal Pathway |
| Related Disease | Parkinson's disease |
